A
33.21
0.07 (0.21%)
| Penutupan Terdahulu | 33.14 |
| Buka | 33.16 |
| Jumlah Dagangan | 3,733,222 |
| Purata Dagangan (3B) | 3,412,650 |
| Modal Pasaran | 4,131,091,456 |
| Harga / Jualan (P/S) | 5.96 |
| Harga / Buku (P/B) | 18.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -34.97% |
| Margin Operasi (TTM) | -24.02% |
| EPS Cair (TTM) | -2.03 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 78.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 198.40% |
| Nisbah Semasa (MRQ) | 4.36 |
| Aliran Tunai Operasi (OCF TTM) | -205.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -140.21 M |
| Pulangan Atas Aset (ROA TTM) | -16.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -106.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Apellis Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.5 |
| Purata | -0.60 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 13.98% |
| % Dimiliki oleh Institusi | 99.14% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (Needham, 80.67%) | Beli |
| Median | 38.00 (14.42%) | |
| Rendah | 24.00 (RBC Capital, -27.73%) | Pegang |
| Purata | 40.85 (23.01%) | |
| Jumlah | 6 Beli, 7 Pegang | |
| Harga Purata @ Panggilan | 29.08 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 17 Dec 2024 | 36.00 (8.40%) | Pegang | 34.53 |
| 06 Nov 2024 | 36.00 (8.40%) | Beli | 28.83 | |
| Morgan Stanley | 21 Nov 2024 | 31.00 (-6.65%) | Pegang | 27.75 |
| Baird | 07 Nov 2024 | 55.00 (65.61%) | Beli | 28.74 |
| B of A Securities | 06 Nov 2024 | 47.00 (41.52%) | Beli | 28.83 |
| Citigroup | 06 Nov 2024 | 51.00 (53.57%) | Beli | 28.83 |
| HC Wainwright & Co. | 06 Nov 2024 | 57.00 (71.64%) | Beli | 28.83 |
| Needham | 06 Nov 2024 | 60.00 (80.67%) | Beli | 28.83 |
| Oppenheimer | 06 Nov 2024 | 40.00 (20.45%) | Beli | 28.83 |
| Piper Sandler | 06 Nov 2024 | 32.00 (-3.64%) | Pegang | 28.83 |
| RBC Capital | 06 Nov 2024 | 24.00 (-27.73%) | Pegang | 28.83 |
| 04 Nov 2024 | 25.00 (-24.72%) | Pegang | 28.56 | |
| Scotiabank | 06 Nov 2024 | 30.00 (-9.67%) | Pegang | 28.83 |
| 16 Oct 2024 | 35.00 (5.39%) | Pegang | 27.95 | |
| Wells Fargo | 06 Nov 2024 | 30.00 (-9.67%) | Pegang | 28.83 |
| Mizuho | 24 Oct 2024 | 38.00 (14.42%) | Pegang | 27.58 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |